



: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No Visit ID : CKHA.0000066179

Ref Doctor

: CKHAOPV97119

Emp/Auth/TPA ID

: Dr.SELF : 169858 Collected

: 05/May/2023 09:01AM

Received : 05/May/2023 01:23PM

: 05/May/2023 02:31PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

PERIPHERAL SMEAR, WHOLE BLOOD-EDTA

RBCs ARE NORMOCYTIC NORMOCHROMIC.ANISOCYTOSIS+.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN







: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No Visit ID

: CKHA.0000066179

Ref Doctor

: CKHAOPV97119

Emp/Auth/TPA ID

: Dr.SELF : 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:23PM : 05/May/2023 02:31PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

| ARCOFEMI - MEDIWHEEL - FULL BODY | PLUS ANNUAL CHE | CK ADVANCED | HC MALE - 2D ECHO - | PAN INDIA - FY2324 |
|----------------------------------|-----------------|-------------|---------------------|--------------------|
| Test Name | Result | Unit | Bio. Ref. Range | Method |

| CV BC COUNT | 48.30 | | | |
|---------------------------------------|---------|-------------------------|---------------|--------------------------------|
| BC COUNT | | % | 40-50 | Electronic pulse & Calculation |
| | 5.8 | Million/cu.mm | 4.5-5.5 | Electrical Impedence |
| 1CV | 83.2 | fL | 83-101 | Calculated |
| 1CH | 27.7 | pg | 27-32 | Calculated |
| 1CHC | 33.3 | g/dL | 31.5-34.5 | Calculated |
| r.D.W | 17.7 | % | 11.6-14 | Calculated |
| OTAL LEUCOCYTE COUNT (TLC) | 5,890 | cells/cu.mm | 4000-10000 | Electrical Impedanc |
| OIFFERENTIAL LEUCOCYTIC COUNT (| DLC) | | | |
| IEUTROPHILS | 57.3 | % | 40-80 | Electrical Impedanc |
| YMPHOCYTES | 31.7 | % | 20-40 | Electrical Impedance |
| OSINOPHILS | 2.3 | % | 1-6 | Electrical Impedanc |
| ONOCYTES | 8.3 | % | 2-10 | Electrical Impedanc |
| ASOPHILS | 0.4 | % | <1-2 | Electrical Impedanc |
| BSOLUTE LEUCOCYTE COUNT | • | | | |
| IEUTROPHILS | 3374.97 | Cells/cu.mm | 2000-7000 | Electrical Impedanc |
| YMPHOCYTES | 1867.13 | Cells/cu.mm | 1000-3000 | Electrical Impedanc |
| OSINOPHILS | 135.47 | Cells/cu.mm | 20-500 | Electrical Impedanc |
| ONOCYTES | 488.87 | Cells/cu.mm | 200-1000 | Electrical Impedanc |
| ASOPHILS | 23.56 | Cells/cu.mm | 0-100 | Electrical Impedanc |
| LATELET COUNT | 219000 | cells/cu.mm | 150000-410000 | Electrical impedenc |
| RYTHROCYTE SEDIMENTATION ATE (ESR) | 3 | mm at the end of 1 hour | 0-15 | Modified Westergre |

RBCs ARE NORMOCYTIC NORMOCHROMIC.ANISOCYTOSIS+.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN

Page 2 of 16





Patient Name : Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No

Visit ID

: CKHA.0000066179

Ref Doctor

: CKHAOPV97119

: Dr.SELF Emp/Auth/TPA ID : 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:23PM : 05/May/2023 03:15PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

| ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHEC | CK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324 |
|---|--|
|---|--|

Test Name Result Unit Bio. Ref. Range Method

| BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD-EDTA | | | | |
|---|----------|--------------------------------|--|--|
| BLOOD GROUP TYPE | AB | Microplate Hemagglutination | | |
| Rh TYPE | Positive | Microplate Hemagglutination | | |





: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No Visit ID

: CKHA.0000066179

Ref Doctor

: CKHAOPV97119

: Dr.SELF Emp/Auth/TPA ID : 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:25PM

Reported

: 05/May/2023 02:04PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANN | IUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324 |
|---|--|
|---|--|

| Test Name | Result | Unit | Bio. Ref. Range | Method |
|-----------|--------|------|-----------------|--------|

GLUCOSE, FASTING, NAF PLASMA 96 mg/dL 70-100 HEXOKINASE

Comment:

As per American Diabetes Guidelines

| Fasting Glucose Values in mg/d L | Interpretation |
|----------------------------------|----------------|
| <100 mg/dL | Normal |
| 100-125 mg/dL | Prediabetes |
| ≥126 mg/dL | Diabetes |





: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No Visit ID : CKHA.0000066179

Ref Doctor

: CKHAOPV97119

: Dr.SELF

Emp/Auth/TPA ID : 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:22PM

Reported Status : 05/May/2023 03:51PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| ARCOFEMI - MEDIWHEEL - FULL BODY | PLUS ANNUAL CHE | CK ADVANCED | HC MALE - 2D ECHO - | PAN INDIA - FY2324 |
|----------------------------------|-----------------|-------------|---------------------|--------------------|
| Test Name | Result | Unit | Bio. Ref. Range | Method |

| GLUCOSE, POST PRANDIAL (PP), 2 | 90 | mg/dL | 70-140 | HEXOKINASE |
|--------------------------------|----|-------|--------|------------|
| HOURS , NAF PLASMA | | | | |

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Ref: Marks medical biochemistry and clinical approach





Patient Name : Mr.GAURAV GOSAVI

Age/Gender : 37 Y 6 M 0 D/M

UHID/MR No : CKHA.0000066179

Visit ID : CKHAOPV97119

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 169858 Collected : 05/May/2023 09:01AM

Received : 05/May/2023 01:22PM Reported : 05/May/2023 03:51PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| ARCOFEMI - MEDIWHEEL - FULL BODY | PLUS ANNUAL CHE | CK ADVANCED | HC MALE - 2D ECHO - | PAN INDIA - FY2324 |
|----------------------------------|-----------------|-------------|---------------------|--------------------|
| Test Name | Result | Unit | Bio. Ref. Range | Method |

| HBA1C, GLYCATED HEMOGLOBIN, | 5.3 | % | HPLC |
|----------------------------------|-----|-------|------------|
| WHOLE BLOOD-EDTA | | | |
| ESTIMATED AVERAGE GLUCOSE (eAG), | 105 | mg/dL | Calculated |
| WHOLE BLOOD EDTA | | | |

Comment:

Reference Range as per American Diabetes Association (ADA):

| REFERENCE GROUP | HBA1C IN % |
|-------------------------------|------------|
| NON DIABETIC ADULTS >18 YEARS | <5.7 |
| AT RISK (PREDIABETES) | 5.7 – 6.4 |
| DIAGNOSING DIABETES | ≥ 6.5 |
| DIABETICS | |
| · EXCELLENT CONTROL | 6 – 7 |
| · FAIR TO GOOD CONTROL | 7 – 8 |
| · UNSATISFACTORY CONTROL | 8 – 10 |
| · POOR CONTROL | >10 |

Note: Dietary preparation or fasting is not required.

- 1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control).
- 2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1 and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
- 3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control

Page 6 of 16







Patient Name : Mr.GAURAV GOSAVI

Age/Gender : 37 Y 6 M 0 D/M

UHID/MR No : CKHA.0000066179

Visit ID : CKHAOPV97119

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 169858

Collected : 05/May/2023 09:01AM

Received : 05/May/2023 01:29PM Reported : 05/May/2023 02:59PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY

| ARCOFEMI - MEDIWHEEL - FULL BODY | PLUS ANNUAL CHE | CK ADVANCED | HC MALE - 2D ECHO - | PAN INDIA - FY2324 |
|----------------------------------|-----------------|-------------|---------------------|--------------------|
| Test Name | Result | Unit | Bio. Ref. Range | Method |

| LIPID PROFILE , SERUM | | | | |
|-----------------------|--------|-------|--------|-------------------------------|
| TOTAL CHOLESTEROL | 213 | mg/dL | <200 | CHO-POD |
| TRIGLYCERIDES | 112 | mg/dL | <150 | GPO-POD |
| HDL CHOLESTEROL | 50 | mg/dL | 40-60 | Enzymatic Immunoinhibition |
| NON-HDL CHOLESTEROL | 163 | mg/dL | <130 | Calculated |
| LDL CHOLESTEROL | 140.21 | mg/dL | <100 | Calculated |
| VLDL CHOLESTEROL | 22.35 | mg/dL | <30 | Calculated |
| CHOL / HDL RATIO | 4.22 | | 0-4.97 | Calculated |

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

| | Desirable | Borderline High | High | Very High |
|---------------------|--|-----------------|-----------|-----------|
| TOTAL CHOLESTEROL | < 200 | 200 - 239 | ≥ 240 | |
| TRIGLYCERIDES | <150 | 150 - 199 | 200 - 499 | ≥ 500 |
| | Optimal < 100 Near Optimal 100-129 | 130 - 159 | 160 - 189 | ≥ 190 |
| HDL | <u>≥</u> 60 | | | |
| INON-HOLCHOLESTEROL | Optimal <130; Above Optimal 130-159 | 160-189 | 190-219 | >220 |

Measurements in the same patient can show physiological and analytical variations.

NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.





: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No Visit ID : CKHA.0000066179

Ref Doctor Emp/Auth/TPA ID : CKHAOPV97119

: Dr.SELF : 169858 Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:29PM : 05/May/2023 02:59PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324 |
|--|
|--|

| Test Name | Result | Unit | Bio. Ref. Range | Method |
|-----------|--------|------|-----------------|--------|
|-----------|--------|------|-----------------|--------|

| LIVER FUNCTION TEST (LFT), SERUM | | | | |
|---------------------------------------|-------|-------|---------|-----------------------|
| BILIRUBIN, TOTAL | 1.20 | mg/dL | 0.3–1.2 | DPD |
| BILIRUBIN CONJUGATED (DIRECT) | 0.22 | mg/dL | <0.2 | DPD |
| BILIRUBIN (INDIRECT) | 0.98 | mg/dL | 0.0-1.1 | Dual Wavelength |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) | 26.24 | U/L | <50 | IFCC |
| ASPARTATE AMINOTRANSFERASE (AST/SGOT) | 24.9 | U/L | <50 | IFCC |
| ALKALINE PHOSPHATASE | 51.71 | U/L | 30-120 | IFCC |
| PROTEIN, TOTAL | 7.69 | g/dL | 6.6-8.3 | Biuret |
| ALBUMIN | 4.54 | g/dL | 3.5-5.2 | BROMO CRESOL GREEN |
| GLOBULIN | 3.15 | g/dL | 2.0-3.5 | Calculated |
| A/G RATIO | 1.44 | ¥: | 0.9-2.0 | Calculated |





: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No Visit ID

: CKHA.0000066179

Ref Doctor

: CKHAOPV97119

: Dr.SELF Emp/Auth/TPA ID : 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:29PM : 05/May/2023 02:59PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

| | DEPARTMENT OF BIOCHEMISTRY | | | | |
|----------------------------------|----------------------------|-------------|---------------------|--------------------|--|
| ARCOFEMI - MEDIWHEEL - FULL BODY | PLUS ANNUAL CHE | CK ADVANCED | HC MALE - 2D ECHO - | PAN INDIA - FY2324 | |
| Test Name | Result | Unit | Bio, Ref, Range | Method | |

| RENAL PROFILE/KIDNEY FUNCTION | TEST (RFT/KFT) , SERU | IM . | | |
|-------------------------------|-----------------------|--------|-------------|-----------------------------|
| CREATININE | 0.92 | mg/dL | 0.72 – 1.18 | Modified Jaffe, Kinetic |
| UREA | 20.07 | mg/dL | 17-43 | GLDH, Kinetic Assay |
| BLOOD UREA NITROGEN | 9.4 | mg/dL | 8.0 - 23.0 | Calculated |
| URIC ACID | 5.18 | mg/dL | 3.5–7.2 | Uricase PAP |
| CALCIUM | 9.77 | mg/dL | 8.8-10.6 | Arsenazo III |
| PHOSPHORUS, INORGANIC | 2.77 | mg/dL | 2.5-4.5 | Phosphomolybdate Complex |
| SODIUM | 141.53 | mmol/L | 136–146 | ISE (Indirect) |
| POTASSIUM | 4.6 | mmol/L | 3.5–5.1 | ISE (Indirect) |
| CHLORIDE | 100.74 | mmol/L | 101–109 | ISE (Indirect) |





: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No

: CKHA.0000066179

Visit ID Ref Doctor : CKHAOPV97119

Emp/Auth/TPA ID

: Dr.SELF : 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:29PM : 05/May/2023 02:11PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| | ARCOFEMI - MEDIWHEEL | - FULL BODY PLUS ANNUAL | _ CHECK ADVANCED HC MALE | - 2D ECHO - PAN INDIA - | - FY2324 |
|--|----------------------|-------------------------|--------------------------|-------------------------|----------|
|--|----------------------|-------------------------|--------------------------|-------------------------|----------|

| Test Name | Result | Unit | Bio. Ref. Range | Method |
|-----------|--------|------|-----------------|--------|

| ALKALINE PHOSPHATASE, SERUM | 51.71 | U/L | 30-120 | IFCC |
|-----------------------------|-------|-----|--------|------|





: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No Visit ID

: CKHA.0000066179

Ref Doctor

: CKHAOPV97119

Emp/Auth/TPA ID

: Dr.SELF

: 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:29PM : 05/May/2023 02:59PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

| ARCOFEMI - MEDIWHEEL | FULL BODY PLUS ANNUA | L CHECK ADVANCED HC MALE | - 2D ECHO - PAN INDIA - F | Y2324 |
|-----------------------------|----------------------|--------------------------|---------------------------|-------|
| | | | | |

| Test Name Result | Unit | Bio. Ref. Range | Method |
|------------------|------|-----------------|--------|
|------------------|------|-----------------|--------|

GAMMA GLUTAMYL TRANSPEPTIDASE (GGT), SERUM

26.78

U/L

<55

IFCC

Page 11 of 16





Patient Name : Mr.GAURAV GOSAVI

Age/Gender : 37 Y 6 M 0 D/M

UHID/MR No : CKHA.0000066179

Visit ID : CKHAOPV97119

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 169858

Collected : 05/May/2023 09:01AM

Received : 05/May/2023 01:28PM Reported : 05/May/2023 02:24PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF IMMUNOLOGY

| ARCOFEMI - MEDIWHEEL - FULL BODY | PLUS ANNUAL CHE | CK ADVANCED | HC MALE - 2D ECHO - | PAN INDIA - FY2324 |
|----------------------------------|-----------------|-------------|---------------------|--------------------|
| Test Name | Result | Unit | Bio. Ref. Range | Method |

| THYROID PROFILE TOTAL (T3, T4, TSH), SERUM | | | | | |
|--|-------|--------|------------|------|--|
| TRI-IODOTHYRONINE (T3, TOTAL) | 1.04 | ng/mL | 0.7-2.04 | CLIA | |
| THYROXINE (T4, TOTAL) | 8.06 | μg/dL | 6.09-12.23 | CLIA | |
| THYROID STIMULATING HORMONE (TSH) | 0.951 | μIU/mL | 0.34-5.60 | CLIA | |

Comment:

Serum TSH concentrations exhibit a diurnal variation with the peak occurring during the night and the nadir occurring between 10 a.m. and 4 p.m.In primary hypothyroidism, thyroid-stimulating hormone (TSH) levels will be elevated. In primary hyperthyroidism, TSH levels will be low. Elevated or low TSH in the context of normal free thyroxine is often referred to as subclinical hypo- or hyperthyroid-ism, respectively. Physiological rise in Total T3 / T4 levels is seen in pregnancy and in patients on steroid therapy.

Recommended test for T3 and T4 is unbound fraction or free levels as it is metabolically active.

Note:

| For pregnant females | Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association) |
|----------------------|--|
| First trimester | 0.1 - 2.5 |
| Second trimester | 0.2 - 3.0 |
| Third trimester | 0.3 - 3.0 |





Patient Name : Mr.GAURAV GOSAVI

Age/Gender : 37 Y 6 M 0 D/M

UHID/MR No : CKHA.0000066179

Visit ID : CKHAOPV97119

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 169858 Collected : 05/May/2023 09:01AM

Received : 05/May/2023 01:28PM Reported : 05/May/2023 02:32PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

| ARCOFEMI - MEDIWHEEL - FULL BODY | PLUS ANNUAL CHE | CK ADVANCED | HC MALE - 2D ECHO - | PAN INDIA - FY2324 |
|----------------------------------|-----------------|-------------|---------------------|--------------------|
| Test Name | Result | Unit | Bio. Ref. Range | Method |

VITAMIN D (25 - OH VITAMIN D) , SERUM 12.01 ng/mL CLIA

Comment:

BIOLOGICAL REFERENCE RANGES

| VITAMIN D STATUS | VITAMIN D 25 HYDROXY (ng/mL) |
|------------------|------------------------------|
| DEFICIENCY | <10 |
| INSUFFICIENCY | 10 – 30 |
| SUFFICIENCY | 30 – 100 |
| TOXICITY | >100 |

The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs)

The reference ranges discussed in the preceding are related to total 25-OHD; as long as the combined total is 30 ng/mL or more, the patient has sufficient vitamin D.

Levels needed to prevent rickets and osteomalacia (15 ng/mL) are lower than those that dramatically suppress parathyroid hormone levels (20–30 ng/mL). In turn, those levels are lower than levels needed to optimize intestinal calcium absorption (34 ng/mL). Neuromuscular peak performance is associated with levels approximately 38 ng/mL.

| VITAMIN B12, SERUM | <80 | pg/mL | 180-914 | CLIA |
|--------------------|-----|-------|---------|------|
|--------------------|-----|-------|---------|------|

Comment:

Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception, poor coordination, and affective behavioral changes. A significant increase in RBC MCV may be an important indicator of vitamin B12 deficiency.

Patients taking vitamin B12 supplementation may have misleading results. A normal serum concentration of B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum B12 concentrations are normal.

Page 13 of 16







: Mr.GAURAV GOSAVI

Age/Gender

: 37 Y 6 M 0 D/M

UHID/MR No Visit ID

: CKHA.0000066179

Ref Doctor

: CKHAOPV97119

: Dr.SELF Emp/Auth/TPA ID : 169858

Collected

: 05/May/2023 09:01AM

Received Reported : 05/May/2023 01:28PM : 05/May/2023 02:14PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

| ARCOFEMI - MEDIWHEEL - F | ULL BODY PLUS ANNUAL CHEC | CK ADVANCED HC MALE - : | 2D ECHO - PAN INDIA - FY2324 |
|--------------------------|---------------------------|-------------------------|------------------------------|
| | | | |

Unit **Test Name** Result Bio. Ref. Range Method

TOTAL PROSTATIC SPECIFIC ANTIGEN (tPSA), SERUM

0.520

ng/mL

0-4

CLIA

Page 14 of 16





: Mr.GAURAV GOSAVI

Age/Gender UHID/MR No : 37 Y 6 M 0 D/M

Visit ID

: CKHA.0000066179

Ref Doctor

: CKHAOPV97119

: Dr.SELF Emp/Auth/TPA ID : 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:21PM : 05/May/2023 01:39PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Unit Result Bio. Ref. Range Method

| COMPLETE URINE EXAMINATION (CU | E) , URINE | | | |
|--------------------------------|--------------------|------|------------------|----------------------------|
| PHYSICAL EXAMINATION | | | | |
| COLOUR | PALE YELLOW | | PALE YELLOW | Visual |
| TRANSPARENCY | CLEAR | | CLEAR | Visual |
| pH | 6.5 | | 5-7.5 | DOUBLE INDICATOR |
| SP. GRAVITY | 1.020 | | 1.002-1.030 | Bromothymol Blue |
| BIOCHEMICAL EXAMINATION | | | | |
| URINE PROTEIN | NEGATIVE | | NEGATIVE | PROTEIN ERROR OF INDICATOR |
| GLUCOSE | NEGATIVE | | NEGATIVE | GLUCOSE OXIDASE |
| URINE BILIRUBIN | NEGATIVE | | NEGATIVE | AZO COUPLING REACTION |
| URINE KETONES (RANDOM) | NEGATIVE | - 6 | NEGATIVE | SODIUM NITRO PRUSSIDE |
| UROBILINOGEN | NORMAL | | NORMAL | MODIFED EHRLICH REACTION |
| BLOOD | NEGATIVE | | NEGATIVE | Peroxidase |
| NITRITE | NEGATIVE | | NEGATIVE | Diazotization |
| LEUCOCYTE ESTERASE | NEGATIVE | | NEGATIVE | LEUCOCYTE ESTERASE |
| CENTRIFUGED SEDIMENT WET MOU | JNT AND MICROSCOPY | | | |
| PUS CELLS | 2 - 3 | /hpf | 0-5 | Microscopy |
| EPITHELIAL CELLS | 1 - 2 | /hpf | <10 | MICROSCOPY |
| RBC | NIL | /hpf | 0-2 | MICROSCOPY |
| CASTS | NIL | | 0-2 Hyaline Cast | MICROSCOPY |
| CRYSTALS | ABSENT | | ABSENT | MICROSCOPY |





: Mr.GAURAV GOSAVI

Age/Gender UHID/MR No : 37 Y 6 M 0 D/M

Visit ID

: CKHA.0000066179

Ref Doctor

: CKHAOPV97119

: Dr.SELF Emp/Auth/TPA ID : 169858

Collected

: 05/May/2023 09:01AM

Received

: 05/May/2023 01:22PM

Reported Status

: 05/May/2023 02:10PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

| ARCOFEMI - MEDIWHEEL - FULL BODY PLUS ANNUAL CHECK ADVANCED HC MALE - 2D ECHO - PAN INDIA - FY23 | 24 |
|--|----|
|--|----|

| Test Name | Result | Unit | Bio. Ref. Range | Method |
|-----------|--------|------|-----------------|--------|

| URINE GLUCOSE(POST PRANDIAL) | NEGATIVE | NEGATIVE | Dipstick | |
|------------------------------|----------|----------|----------|--|
| | | | | |

URINE GLUCOSE(FASTING)

NEGATIVE

NEGATIVE

Dipstick

*** End Of Report ***

DR. MANISH T. AKARE M.B.B.S, MD(Path.)

Consultant Pathologist

Dr Sneha Shah

MBBS, MD (Pathology) Consultant Pathologist Dr Sanjay Ingle

M.B.B.S, MD(Pathology) Consultant Pathologist



Patient Name : Mr. Gaurav Gosavi Age/Gender : 37 Y/M

UHID/MR No.

: CKHA.0000066179

Sample Collected on

LRN#

: RAD1991775

Ref Doctor : SELF **Emp/Auth/TPA ID** : 169858 OP Visit No Reported on

Specimen

: CKHAOPV97119 : 05-05-2023 17:24

: 05-05-2023 17:2

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen .

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

CONCLUSION:

No obvious abnormality seen

Dr. SANKET KASLIWAL MBBS DMRE

Radiology



Patient Name : Mr. Gaurav Gosavi Age/Gender : 37 Y/M

UHID/MR No. : CKHA.0000066179 **OP Visit No** : CKHAOPV97119

 Sample Collected on
 : 05-05-2023 09:35

 LRN#
 : RAD1991775
 Specimen
 :

LRN# : RAD1991775 Specimen : Ref Doctor : SELF

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

Liver: appears normal in size, shape and shows normal echotexture. No focal lesion is noted. No e/o IHBR dilatation is seen. Portal vein and CBD appear normal in dimensions at porta hepatis.

Gall bladder: is partially distended with normal wall thickness. No echoreflective calculus or soft tissue mass noted.

Spleen: appears normal in size, shape and echotexture. No focal lesion is noted.

: 169858

Pancreas: appears normal in size, shape and echotexture. No focal lesion / pancreatic ductal dilatation / calcification noted.

Right kidney: normal in size ms 9.8 x 3.9 cms, shape, location with smooth outlines and normal echotexture. CM differentiation is well maintained. No calculus or hydronephrosis seen.

Left kidney: normal in size ms 9.1 x 4.6 cms, shape, location with smooth outlines and normal echotexture. CM differentiation is well maintained. No calculus or hydronephrosis seen.

No retroperitoneal lymphadenopathy is seen. Aorta and I.V.C. appear normal.

Urinary bladder: is well distended and appears normal. No echoreflective calculus or soft tissue mass noted. Both U-V junction appear normal.

Prostate: appears normal in size and echotexture Volume- 18.4 cc .

Visualised bowel loops appear normal. No wall edema or mass noted.

IMPRESSION:

Emp/Auth/TPA ID

• No significant abnormality in present scan.

Clinical correlation suggested....

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

Dr. SANKET KASLIWAL

MBBS DMRE

Radiology